A Clinical Trial to Study the Effects of Revamilast in Patients With Rheumatoid Arthritis (TERRA)

Glenmark Pharmaceuticals

Status and phase: Completed; Phase 2

Conditions: Rheumatoid Arthritis

Treatments: Drug: Placebo Comparator; Drug: Revamilast

Study type: Interventional

Funder types: Industry

Identifiers

NCT01430507

2011-000107-40 (EudraCT Number)

GRC 4039-203

Details and patient eligibility

About

Rheumatoid arthritis (RA) is a systemic autoimmune and chronic inflammatory disease that causes progressive damage to joints of the body, affecting the functional capacity. Effective management of patients with RA requires a multidisciplinary approach. Despite the various combinations, there is a significant population of RA patients who are not responding to these combinations or showing inadequate response to methotrexate alone. Hence, there is a need for a unique combination of drugs targeting different pathological process to yield the best results in those patients where prognosis is poor. Combination of revamilast with first line therapy like methotrexate could provide better treatment options to a larger population of RA patients having moderate to severe disease and who are inadequately controlled on one or the other DMARDs.

This is randomized, double-blind, placebo-controlled, parallel group study. The study will include patients with active RA receiving stable and maximum tolerated dose of MTX.

Patients will be recruited after providing written informed consent. After screening and run in period (single blind placebo for 4 weeks), patients will be randomized (meeting randomization criteria) in 1:2:2:2 ratios to receive either one of three doses (Low, Medium and High) of revamilast or placebo along with MTX.

The primary objective of the study is to determine the percentage of patients achieving ACR20 response at 12 weeks. Secondary objectives include determining percentage of patients with ACR50 and ACR70 response, change in DAS-28 score, change in serum CRP and ESR values and frequency and use of rescue medication.

During the treatment period, there will be 5 further study visits at week 2, week 4, week 8, week 12, for efficacy, safety and tolerability assessment and visit at week 14 will be follow up visit.

Enrollment: 406 patients

Sex: All

Ages: 18 to 65 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

1. Male or female ≥18 to ≤ 65 years of age

2. Documented history of RA; diagnosed according to the revised American College of Rheumatology criteria (ACR)

3. Active RA defined as patients with:

   • 6 swollen joint counts

   • 6 tender/painful joint counts, and

     • At least two of the three following criteria:

       • Rheumatoid Factor positive or Anti CCP positive
       • CRP ≥1.2 times upper limit of normal reference range or ESR >28 mm/hr
       • Morning stiffness lasting >45 min for at least last4 weeks

4. DAS-28 CRP values ≥ 4.5 at screening (visit 1)

5. Patients must have been on stable (15 mg to 25 mg) or maximum tolerated dose of MTX for at least 12 weeks prior to screening

6. The patient's written informed consent to participate in the study

7. Female participants must have a negative serum pregnancy test at screening visit.

8. Males must agree to use barrier while on study medication and for 90 days after taking the last dose of study medication

9. Must meet the following laboratory criteria:

   • Hemoglobin ≥ 9 g/dL
   • White blood cell (WBC) count; ≥3.0 X 109/L
   • Platelet count ≥ 100,000 /L (100 X 109/L)
   • Serum creatinine <1.5 mg/dL (or 133mol/L)
   • Total bilirubin <2.0 mg/dL
   • AST & ALT<1.5 times upper limit of normal

Exclusion criteria

1. Diagnosis of RA prior to 16 years of age (Juvenile RA)
2. Non-degenerative joint diseases or other joint diseases that could interfere with the evaluation of RA
3. Patients with any other autoimmune rheumatic disorders with the exception of Sjogren's syndrome.
4. Patients with first degree relative with immune deficiency
5. History of infection with human immunodeficiency virus and/or active hepatitis B or C
6. Severe disabling arthritis leaving the patient eligible for surgical intervention, or incapacitated and prostrated patients
7. Patients with a history of drug or alcohol abuse or chronic smoking
8. Uncontrolled diabetes mellitus
9. Concurrent diseases that might interfere with the conduct of the study,
10. ECG abnormalities judged by the investigator to be clinically significant
11. History of using any other test drug, one month before the beginning of this trial
12. Women who are pregnant or breast-feeding or on hormonal therapy
13. Patients who in the Investigator's opinion might not be suitable for the study.
14. Patients with a life expectancy of less than 1 year

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Double Blind

---

406 participants in 4 patient groups, including a placebo group

Medium Dose

Experimental group

Description:

Medium Dose Revamilast

Treatment:

Drug: Revamilast

Drug: Revamilast

Drug: Revamilast

High Dose

Experimental group

Description:

High Dose Revamilast

Treatment:

Drug: Revamilast

Drug: Revamilast

Drug: Revamilast

Placebo

Placebo Comparator group

Description:

Matching Placebo in Triple Dummy Format

Treatment:

Drug: Placebo Comparator

Low dose

Experimental group

Description:

Low dose Revamilast

Treatment:

Drug: Revamilast

Drug: Revamilast

Drug: Revamilast